RxDoctor Payments Data

Frank Russo

Nurse Practitioner · Asheville, NCNPI 1437305786

Payments from drug & device makers

$8,293in general payments, 2019–2025

Across 350 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$951
  • Alkermes, Inc.$619
  • Neurocrine Biosciences, Inc.$561
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$8,13498%
  • Education$1582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,293 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$12,879
Medicare patients
49
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$193,929
VraylarCariprazine Hcl26$72,693
Invega SustennaPaliperidone Palmitate11$28,278
Clozapine26$3,232
Aripiprazole18$3,136
Quetiapine Fumarate43$2,864
Olanzapine35$1,479
Lamotrigine67$799
Gabapentin36$770
Bupropion XlBupropion Hcl25$726
Trazodone Hcl63$619
Clonazepam84$577
Lurasidone Hcl13$519
Prazosin Hcl16$509
Hydroxyzine Hcl18$476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$951$193,92914 claims
AbbVieVraylar$1,553$72,69326 claims
Johnson & JohnsonInvega Sustenna$266$28,27811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →